News | Peptide Synthesizers & Consumables | Gyros Protein Technologies

Purepep Chorus Automated Peptide Synthesizer | PurePep Blog

Written by Walter Lentfert | Sep 4, 2019 6:00:00 AM
  • Flexible, modular system, designed for 21CFR Part 11 compliance
  • Delivers high purity, productivity and yield for simple to complex peptides

Uppsala, Sweden, and Tucson, AZ, USA, 04 September 2019: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassay platforms and leading provider of peptide synthesizers and reagents, today introduced PurePep™ Chorus, its next generation automated peptide synthesis platform. The new scalable instrument and software platform enables production of even the most challenging sequences at the highest possible crude purity and yield.

Scientists using peptides in development of novel therapeutics, biological research, or biomaterials development frequently work on long and difficult sequences, including modified cyclic peptides. These are particularly challenging to synthesize at sufficiently high purity and yield, and often require precious or expensive reagents.

Designed to overcome these issues and make these advancements accessible to both academic and industrial scientists, PurePep Chorus has a modular design, enabling in-lab upgrades aligned with the growing needs of peptide researchers. The flexible system can be purchased with, or lab-upgraded to include, two, four, or six channels, with independent induction heating, and real-time UV monitoring on two or more channels, depending upon researchers’ needs and budgets.

 PurePep Chorus also employs flexible programming and Single-Shot™ additions, to eliminate the need for priming while minimizing waste when using special amino acids and reagents. The instrument incorporates an intuitive interface software that simplifies the chemist’s workflows, accelerates set-up with pre-programmed methods, while also being designed for 21 CFR part 11 compliance.

 

Jasmine Gruia-Gray, SVP Marketing, Gyros Protein Technologies, said: “This latest instrument harnesses the power of our proprietary PurePep Pathway in a modular design, maximizing purity and providing industry-leading productivity and flexibility. The new software has many new features, including the ability to program the next synthesis while the instrument is running.”

Gyros Protein Technologies will be showcasing PurePep Chorus and data at various conferences across Asia Pacific, Europe and the United States over the coming months.

For more information please visit: PurePep Chorus

 

Notes to editors

Image: PurePep™ Chorus peptide synthesizer

For a high resolution image please contact Zyme Communications

 

Media contact:
Katie Odgaard
Zyme Communications
Tel: +44 (0)7787 502 947

Email: katie.odgaard@zymecommunications.com

To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy, please click here.

 

About Gyros Protein Technologies (For more information please click here)

Gyros Protein Technologies, enables peptide synthesis and bioanalytical solutions that help scientists increase biomolecule performance and productivity in research, drug discovery, pre-clinical and clinical development, and bioprocess applications.  Our low to mid-scale peptide synthesizer platforms are PurePep Chorus,Tribute®, Prelude® X, Symphony® X, and Sonata®. These solutions and our chemistries deliver uncompromising purity, flexibility, and quality for discovery and pre-clinical studies of simple to complex multifunctional peptides. Proprietary high performance nanoliter-scale immunoassay platforms, Gyrolab® xPand, Gyrolab® xP workstation and Gyrolab xPlore™, are used by scientists in leading pharmaceutical, biotech, CRO, and CMO companies for bioanalytical applications such as pharmacokinetics/pharmacodynamics, immunogenicity, and quantitating bioprocess-related impurities. Our peptide synthesis and bioanalytical solutions accelerate your discovery, development, and manufacturing of safer biotherapeutics.